Satoh Kanako, Nonaka Ryouichi, Tada Yukie, Fukumori Nobutaka, Ogata Akio, Yamada Arisa, Satoh Tsuyoshi, Nagai Fumiko
Department of Environmental Health and Toxicology, Tokyo Metropolitan Institute of Public Health, 24-1 Hyakunincho 3-chome, 169-0073 Shinjuku-ku, Tokyo, Japan.
Arch Toxicol. 2006 Sep;80(9):605-13. doi: 10.1007/s00204-006-0082-4. Epub 2006 Feb 23.
Many cases of hepatopathy including deaths have frequently occurred after ingestion of Chinese dietary supplements for weight loss containing N-nitrosofenfluramine (N-fen), a nitroso derivative of fenfluramine (Fen), which was used for the treatment of obesity in the United States. Since Fen decreases appetite by decreasing the serotonin level and exhibits an antibiotic effect, N-fen may have been added, expecting a similar effect. Thus, we synthesized N-fen and orally administered it to mice, and investigated its effect on the liver as well as on the cerebral serotonin nervous system to investigate whether N-fen exhibits an anorectic effect. Three doses of N-fen were orally administered once daily to mice for 1 week. No significant changes in body weight, food intake, and general condition were noted. The liver and kidney weights were significantly increased. On blood chemistry, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase activities were increased, and total bilirubin and albumin were slightly decreased. On histopathological examination, acidophilic changes and mild cellular swelling were noted in the liver. The liver drug-metabolizing enzyme (P-450) level was significantly higher. The effect of N-fen on the serotonin (5HT) nervous system was examined by quantitative autoradiography of the mouse brain, and it was found that N-fen did not decrease the 5HT nerve activity. Effects of reuptake and release of monoamine neurotransmitters [dopamine (DA), 5HT, and norepinephrine (NE)] were investigated. N-fen inhibited a little 5HT reuptake, and did not inhibit reuptakes of DA and NE. Moreover, N-fen did not affect release of the three monoamines. The above findings suggested that N-fen did not exhibit a serotonin nerve fiber-mediated anorectic effect in mice, but induced hepatopathy.
在美国,曾被用于治疗肥胖症的芬氟拉明(Fen)的亚硝基衍生物N-亚硝基芬氟拉明(N-fen),被添加到一些用于减肥的中国膳食补充剂中。摄入这些含N-fen的膳食补充剂后,经常会出现包括死亡在内的许多肝病病例。由于芬氟拉明通过降低血清素水平来减少食欲,并具有抗菌作用,因此添加N-fen可能是期望获得类似效果。于是,我们合成了N-fen并将其口服给予小鼠,研究其对肝脏以及大脑血清素神经系统的影响,以探究N-fen是否具有厌食作用。将三种剂量的N-fen每天口服一次给予小鼠,持续1周。未观察到体重、食物摄入量和一般状况有显著变化。肝脏和肾脏重量显著增加。血液生化检查显示,碱性磷酸酶、天冬氨酸氨基转移酶和丙氨酸氨基转移酶活性升高,总胆红素和白蛋白略有下降。组织病理学检查发现,肝脏出现嗜酸性变化和轻度细胞肿胀。肝脏药物代谢酶(P-450)水平显著升高。通过对小鼠大脑进行定量放射自显影检查N-fen对血清素(5HT)神经系统的影响,发现N-fen并未降低5HT神经活性。研究了单胺神经递质[多巴胺(DA)、5HT和去甲肾上腺素(NE)]的再摄取和释放作用。N-fen对5HT再摄取有轻微抑制作用,对DA和NE的再摄取无抑制作用。此外,N-fen对三种单胺的释放没有影响。上述研究结果表明,N-fen在小鼠中未表现出血清素神经纤维介导的厌食作用,但会诱发肝病。